Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Legend Biotech Corporation (NASDAQ: LEGN) will participate in the 40th Annual J.P. Morgan Healthcare Conference virtually on Tuesday, January 11, 2022, at 2:15 p.m. ET. CEO Ying Huang will present, and the live webcast will be accessible on the Legend Biotech website. The company focuses on developing cell therapies targeting life-threatening diseases.
Notably, their lead product, ciltacabtagene autoleucel, is under regulatory review for treating multiple myeloma, with evaluations by the FDA and EMA ongoing.
- None.
- None.
A live webcast of the presentation will be available to investors and other interested parties at the
About
We are currently engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. Applications seeking approval of cilta-cel for the treatment of patients with RRMM are currently under regulatory review by several health authorities around the world, including the
Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.
Cautionary Statement:
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of our product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial or preclinical study results, including as a result of additional analysis of existing data or unexpected new data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005287/en/
Investor Contacts:
Joanne.choi@legendbiotech.com
crystal.chen@legendbiotech.com
Press Contact:
tina.carter@legendbiotech.com
(908) 331-5025
Source:
FAQ
When is Legend Biotech's presentation at the J.P. Morgan Healthcare Conference?
Who will present for Legend Biotech at the conference?
Where can I watch Legend Biotech's conference presentation?
What is the focus of Legend Biotech's research?
What is ciltacabtagene autoleucel?
Which regulatory bodies are reviewing Legend Biotech's lead product?
